Navigation Links
Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Date:11/2/2007

BRISBANE, Australia, Nov. 2 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs will present a poster entitled "The Interactive Effect of Prognostic Factors and PI-88 Use on the Delay of HCC Recurrence Following Curative Partial Hepatic Resection" at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA(1) on Saturday, 3 November 2007.

The poster presentation will be made available on Progen's website http://www.progen-pharma.com from approximately 9am (Brisbane time) Saturday 3 November 2007.

(1) Each year, the American Association for the Study of Liver Diseases brings together over 6,000 hepatologists and hepatology health professionals from around the world for its annual meeting to meet and exchange the latest liver disease research, and discuss treatment outcomes.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In a phase 2 trial in post- resection liver cancer, 160mg of PI-88 demonstrated a 25% improvement in the primary endpoint of disease-free rate at 48 weeks and 78% improvement in secondary endpoint of disease-free survival. These results, combined with positive feedback from the FDA, provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

About Progen: Progen Pharmaceuticals Limited is an Australia-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The secrets for a healthy progeny: Mother’s diet during pregnancy
2. Lizard Mothers Dress Their Progeny to Ensure Success in Later Life
3. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
4. Researchers Present Ways To Reduce The Risk Of Dementia
5. Researchers Present Data Regarding The Efficiency Of Herbs
6. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
7. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
8. Drug Reactions First Present Themselves In The Mouth
9. Reminiscing Into The Past Makes You Dissatisfied With The Present
10. Living In The Past Indicates Dissatisfaction With Present
11. Movies Represent Coma In A Wrong Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... problems ranging from gum disease to enamel erosion, and those dental problems can ... Department of Public Health, many pregnant women are failing to get the dental ...
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer of premium ... South Dixie Hwy in Miami, FL. , “We are elated to be opening this ... in-store concept is designed to give clients a seamless and motivating shopping experience.” , ...
(Date:1/17/2017)... ... January 17, 2017 , ... Healthful Balance announces ... company, owned and operated by Ed Stroup, was created to offer the highest ... highest level of customer service. Healthful Balance products can be purchased online through ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... Metairie, Louisiana (PRWEB) , ... January 17, 2017 ... ... JenCare Senior Medical Center joined the Peoples Health network on Dec. 1, ... Medicare beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 North ... GlobalData,s new report, "North America Insulin Delivery Market ... North America Insulin Delivery market. The report provides value, ... average prices (USD) within market segments - Insulin Pens, ... The report also provides company shares and distribution ...
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... System Market 2016-2020" report to their offering. ... The global artificial pancreas devices ... period 2016-2020. Global Artificial Pancreas Devices System Market 2016-2020, ... from industry experts. The report covers the market landscape and its ...
(Date:1/17/2017)... DUBLIN , Jan 17, 2017 ... for Self Healing Materials: 2017 - 2024" report to their ... This ... last full market report that was issued in May of 2015. ... market potential. In our previous analysis we projected a market potential ...
Breaking Medicine Technology: